insights_auto
Outlook: 66.7% bullish·1.8% bearish
Go to analysischevron_right
REGN:NASDAQ
Regeneron Pharmaceuticals Inc
$746.54
arrow_upward
+0.94%(+6.97) 1D
$745.55
arrow_downward
-0.13% (-0.99)bedtimeAfter hours
Closed: Oct 9, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for REGN...
Open
$737.20
High
$751.27
Low
$732.83
Mkt. cap
76.86B
Avg. vol.
720.68K
Volume
466.03K
Dividend
0.50%
Quarterly dividend
$0.94
Ex-dividend date
Aug 18, 2026
P/E ratio
18.46
52-wk high
$859.34
52-wk low
$541.00
EPS
$40.45
Beta
0.16
Shares outstanding
101.14M
No. of employees
15K
Open
$737.20
High
$751.27
Low
$732.83
Mkt. cap
76.86B
Avg. vol.
720.68K
Volume
466.03K
Dividend
0.50%
Quarterly dividend
$0.94
Ex-dividend date
Aug 18, 2026
P/E ratio
18.46
52-wk high
$859.34
52-wk low
$541.00
EPS
$40.45
Beta
0.16
Shares outstanding
101.14M
No. of employees
15K
News stories
From web sources and news partners
Simply Wall Street
·
26 minutes ago
Regeneron Pharmaceuticals (REGN) Gets A Fresh Look As Trial Wins And Sanofi Deal Feed Value Narrative
Stock Traders Daily
·
22 hours ago
How (REGN) Movements Inform Risk Allocation Models
Zacks
·
1 day ago
Why Regeneron (REGN) is a Top Value Stock for the Long-Term
Trefis
·
1 day ago
What Is Going On With Regeneron Stock?
Profile
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap. Wikipedia
About Regeneron Pharmaceuticals Inc
CEOLeonard Schleifer
Employees15.3K
Founded1988
HeadquartersTarrytown, New York, United States
SectorBiotechnology
Websiteregeneron.com